NCT07838636

Brief Summary

Parkinson's disease is a common, progressive neurodegenerative disorder. The degeneration of dopaminergic neurons is associated with characteristic clinical symptoms such as tremor, rigidity, slowness of movement (bradykinesia) and postural instability. Subthalamic nucleus deep brain stimulation (DBS-STN) is a recognized and widely used method of treating advanced stages of Parkinson's disease. It improves clinical symptoms such as tremor, rigidity and slowness of movement (bradykinesia). This method has limited application for late motor and non-motor symptoms such as: akinesia, postural instability, gait, including the phenomenon of "freezing", recurrent falls, balance and dysarthria. These symptoms reduce the quality of life of patients and make them dependent on their caregivers. There is a clear need to develop additional forms of therapy that complement deep brain stimulation in controlling late motor and non-motor symptoms. Physical activity is a commonly used and recommended form of therapy for patients with Parkinson's disease and a complement to pharmacological therapy, improving gait, balance and quality of life. However, there are no clear recommendations including patients after implantation of DBS-STN stimulators to the group undergoing physiotherapy. To this day, only one clinical trial has been registered assessing the effect of physiotherapy on balance and gait in patients with DBS-STN.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
102

participants targeted

Target at P75+ for not_applicable parkinson-disease

Timeline
24mo left

Started Sep 2024

Longer than P75 for not_applicable parkinson-disease

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress52%
Sep 2024Sep 2028

Study Start

First participant enrolled

September 5, 2024

Completed
2 years until next milestone

First Submitted

Initial submission to the registry

September 17, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

September 24, 2026

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 5, 2027

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

September 5, 2028

Last Updated

September 24, 2026

Status Verified

June 1, 2026

Enrollment Period

3 years

First QC Date

September 17, 2026

Last Update Submit

September 17, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Part III UPDRS-MDS

    Change in full ON-state score (Drugs+DBS) in Part III of the UPDRS-MDS Scale before and after study completion in control vs. study and subsequent study time points.

    2 years

Secondary Outcomes (4)

  • Tinetti Scale

    2 years

  • NFOG-Q

    2 years

  • Berg Balance Scale

    2 years

  • MoCA Scale

    2 years

Study Arms (2)

Research group

EXPERIMENTAL
Procedure: Physiotherapy

Control group

SHAM COMPARATOR
Behavioral: Education about physiotherapy

Interventions

PhysiotherapyPROCEDURE

Assessment of the patient's functional status: 10 Meter Walk (10 MW) Test, Tinetti Test, New Freezing of Gait Questionnaire (NFOG-Q), History of Falling Questionaire, Timed up and go (TUG), TUG - countdown from 100 to 80, TUG - cup half-filled with water carried in the right and left hand, TST - 10 s standing in a tandem position, 180 Tandem Pivot Test, TWT - Tandem Walking Test, Functional Reach test, Functional strength test, TEST Six Minute Walk (6MWT), Berg Balance Scale, Treadmill Gait Analysis, Platform Stabilometry Test.

Research group

Direct education of the patient in the field of self-care, counseling and instruction on independent exercise, use of medical equipment or devices, also at home.

Control group

Eligibility Criteria

Age50 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients diagnosed with idiopathic Parkinson's disease (ICD-10:G20).
  • Patients qualified for advanced therapies using DBS-STN.
  • Grade II-IV on the Hoehn \& Yahr scale.
  • Age 50-70.
  • Consent to participate in the study.

You may not qualify if:

  • Patients diagnosed with atypical parkinsonism.
  • Patients not eligible for advanced therapies with DBS-STN.
  • Hoehn \& Yahr Grade I and V.
  • Age \<50 and \>70
  • Patients diagnosed with dementia syndrome (MMSE \< 24/30).
  • Diseases of the osteoarticular system and muscles that make it impossible to undergo rehabilitation.
  • Severe kidney, liver and heart failure.
  • Active malignancy or malignancy diagnosed and treated within 3 years prior to the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Neurology, Faculty of Health Sciences, Bródnowski Mazovian Hospital

Warsaw, 03-242, Poland

RECRUITING

MeSH Terms

Conditions

Parkinson Disease

Interventions

Physical Therapy Modalities

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Intervention Hierarchy (Ancestors)

TherapeuticsRehabilitation

Central Study Contacts

Marta M Betka, PhD student

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 17, 2026

First Posted

September 24, 2026

Study Start

September 5, 2024

Primary Completion (Estimated)

September 5, 2027

Study Completion (Estimated)

September 5, 2028

Last Updated

September 24, 2026

Record last verified: 2026-06

Data Sharing

IPD Sharing
Will not share

Locations